Executing the strategy
e-Therapeutics outlined its focused strategy in July, investing in a few select discovery programmes while it looks for partners. Business development activities are underway, as it raises awareness of its network-driven drug (NDD) discovery platform while advancing the immuno-oncology projects to a suitable stage for partnering. Given the proven capabilities of the company and growing interest in big data and artificial intelligence (AI) to enhance drug discovery, we expect e-Therapeutics to have fruitful discussions in the coming year. Our DCF valuation is unchanged at £53.8m or 20.4p/share.
E-Therapeutics is a drug discovery company with a proprietary in silico discovery platform based on the application of network science to the modelling and analysis of cellular processes and utilizing public and proprietary chemical biology and multi-omics data. The therapeutic focus of Co.'s discovery activity is in areas of disease with unmet medical need, including immuno-oncology.
We are experienced healthcare and life sciences analysts providing the highest quality service to companies in these sectors and to investors. We have expertise in the fields of the biotech, medtech , specialty pharma and consumer health sectors.
The old-fashioned values of the City enabled London to become a global financial centre, and we pride ourselves for our integrity and professionalism, where our word is our bond. This applies to our research, and all interactions with companies, the buyside and other partners.
We also firmly believe that by putting our clients first, we create long term value for all stakeholders.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.